soul trial oral semaglutide cardiovascular outcomes results 2025 In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide. #ESCCongress According to the investigators, what
Pay in 4 interest-free payments of $5.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1













